LXRX — LEXICON PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1062822 ·
Last close
$2.34
Market Cap
$1.04B
52W High
$2.68
52W Low
$1.80
ADV30
2,851,157
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 692,000 | 653,000 | -26,540,000 | -31,775,000 | 250,060,000 | 40,924,000 | 75,535,000 |
| Mar 2026 | 21,102,000 | 20,994,000 | -996,000 | -1,043,000 | 268,819,000 | 38,089,000 | 65,963,000 |
| Dec 2025 | 5,493,000 | 5,292,000 | -14,780,000 | -15,530,000 | 184,987,000 | 34,326,000 | 77,449,000 |
| Sep 2025 | 14,182,000 | 14,172,000 | -12,187,000 | -12,769,000 | 205,927,000 | 49,656,000 | 85,768,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,803,000
Investing CF
$2,175,000
Financing CF
$40,829,000
CapEx
$-474,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.07
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,050,401,000
Inventory
$1,196,000
Receivables
$1,643,000
ST Investments
$149,686,000
EBIT TTM
$-52,732,000
Pretax Income TTM
$-61,117,000
Interest Exp TTM
$8,385,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$41,469,000
EBITDA
$-54,023,000
Free Cash Flow
$-44,774,624
Enterprise Value
$914,277,440
Total Cash
$190,610,000
Total Debt
$59,241,000
Shares Out
444,955,934
Trailing EPS
$-0.16
Book Value
$0.39
ROE
-40.2%
ROA
-14.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 49,803,000 | -48,911,000 | -50,341,000 | 184,987,000 | 77,449,000 | — | -67,851,000 |
| Dec 2024 | 31,081,000 | -197,117,000 | -200,403,000 | 298,420,000 | 152,470,000 | — | -178,780,000 |
| Dec 2023 | 1,204,000 | -171,750,000 | -177,119,000 | 229,429,000 | 136,319,000 | — | -161,897,000 |
| Dec 2022 | 139,000 | -100,760,000 | -101,944,000 | 194,299,000 | 77,175,000 | — | -88,851,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,974,000
NetIncome TTM
$-161,845,000
OpCashFlow TTM
$0
Assets (Latest)
$298,420,000
Forward EPS
$-0.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | $1.04B | $19.45 | — |
| OPK | OPKO HEALTH, INC. | $1.04B | $1.40 | — |
| WVE | Wave Life Sciences, Inc. | $1.02B | $5.20 | — |
| ARDX | ARDELYX, INC. | $1.01B | $3.91 | — |
| SVRA | Savara Inc | $1.08B | $5.27 | — |
News headlines (Yahoo Finance, 1h cache)
Lexicon (LXRX) Q2 2026 Earnings Call Transcript
2026-08-13 16:15 · Yahoo
Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings
2026-08-08 00:15 · Yahoo
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
2026-08-06 21:03 · Yahoo
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-30 12:30 · Yahoo
Lexicon Pharmaceuticals (LXRX) As Phase 3 Enrollment Beats Plan Faces An Undervalued View
2026-07-30 08:11 · Yahoo
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
2026-07-27 12:30 · Yahoo
Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion
2026-07-03 13:12 · Yahoo
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?
2026-06-11 18:00 · Yahoo
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
2026-06-11 14:05 · Yahoo
How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates
2026-06-04 13:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.